Share:
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ( Chris ) L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets.
Mr. Stijnen is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company s portfolio in various international subsidiaries between 2005 and March 2020. Most recently he was VP Product & Portfolio Strategy and Interim Head Commercial Strategy and Capabilit
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Personnel
Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer
21.12.2020 / 07:00
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ( Chris ) L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets.
Mr. Stijnen is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company s portfolio in various i
GENEVA, SWITZERLAND / ACCESSWIRE / December 21, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ( Chris ) L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets.
Mr. Stijnen is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company s portfolio in various international subsidiaries between 2005 and March 2020
Happiness Diary: My Experiments with Happiness logo
A unique, practical and effective way of bringing happiness to our daily life with Happiness Diary: My Experiments with Happiness ANI | Updated: Dec 16, 2020 20:29 IST
Gurugram (Haryana) [India], December 16 (ANI/BusinessWire India): The world is going through unprecedented times of COVID-19. COVID-19 has impacted people both economically and healthwise, including mental health. The need for Happiness is now more than ever.
Historically too, India as a country rates poorly in the World Happiness Reports. This is quite unfortunate as one of the oldest civilisations, India, has created and shared a lot of knowledge and practices of Happiness since the beginning of civilisation.
A unique, practical and effective way of bringing happiness australiannews.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from australiannews.net Daily Mail and Mail on Sunday newspapers.